Sorry!! The article you are trying to read is not available now.
Thank you very much;
you're only a step away from
downloading your reports.

Regeneron's Drug Dramatically Lowers Bad Cholesterol Levels for Lipitor Users


A drug developed by Regeneron and Sanofi cut LDL levels in patients by as much as 70% in a study. Amgen also reports success for a similar drug.

Regeneron Pharmaceuticals' (REGN) experimental drug lowered bad cholesterol levels by as much as 70% in a study of patients already taking Lipitor.

The news strengthens Regeneron's early lead in a race to sell a supplemental cholesterol treatment aimed at bringing down LDL -- or bad cholesterol -- levels in patients who already are taking statin drugs such as Pfizer's (PFE) Lipitor. Data from clinical trials in the second of three phases of study usually required for US approval showed Regeneron's drug reduced LDL 40% to 72% depending on dosing.

The results confirmed that earlier, preliminary data suggested the drug worked well in lowering bad cholesterol. Regeneron and partner Sanofi (SNY) are trying to stay a step ahead of competitors, such as Amgen (AMGN), who are trying to develop a similar drug. (See Regeneron's Cholesterol Drug to Get a Closer Look) It should be noted that the drugs will be studied for the next few years and safety profiles of the treatments will be well scrutinized by the Food and Drug Administration.

On Sunday, Amgen said its experimental cholesterol drug AMG 145 lowered LDL by as much as 81%. Amgen is testing its drug in an earlier stage of studies, however. Both Amgen and Regeneron are testing drugs that work by blocking a protein known as PCSK9. Other companies working on similar treatments include Merck (MRK), Bristol-Myers Squibb (BMY), Isis Pharmaceuticals (ISIS), and Alnylam Pharmaceuticals (ALNY).

The companies say they are studying drugs that potentially would help tens of millions of people who can't lower their bad cholesterol simply by taking popular statin medicines such as Lipitor or AstraZeneca's (AZN) Crestor.

"Many patients are not able to lower their (LDL) sufficiently by diet and medication despite the availability of statins," says Dr. James McKenney, CEO of National Clinical Research in Virginia and principal Investigator of the Regeneron study.

Both the Regeneron and Amgen data were presented at a major medical conference, the annual meeting of the American College of Cardiology, in Chicago. Shares of both companies are trading higher late Monday morning. Amgen rose 1.5% to $67.63, while Regeneron is up more than 1% to $120.74.

Twitter: @brettchase

Follow the markets all day every day with a FREE 14 day trial to Buzz & Banter. Over 30 professional traders share their ideas in real-time. Learn more.
< Previous
  • 1
Next >
No positions in stocks mentioned.
The information on this website solely reflects the analysis of or opinion about the performance of securities and financial markets by the writers whose articles appear on the site. The views expressed by the writers are not necessarily the views of Minyanville Media, Inc. or members of its management. Nothing contained on the website is intended to constitute a recommendation or advice addressed to an individual investor or category of investors to purchase, sell or hold any security, or to take any action with respect to the prospective movement of the securities markets or to solicit the purchase or sale of any security. Any investment decisions must be made by the reader either individually or in consultation with his or her investment professional. Minyanville writers and staff may trade or hold positions in securities that are discussed in articles appearing on the website. Writers of articles are required to disclose whether they have a position in any stock or fund discussed in an article, but are not permitted to disclose the size or direction of the position. Nothing on this website is intended to solicit business of any kind for a writer's business or fund. Minyanville management and staff as well as contributing writers will not respond to emails or other communications requesting investment advice.

Copyright 2011 Minyanville Media, Inc. All Rights Reserved.
Featured Videos